Patents Assigned to Sanofi Pasteur S.A.
  • Patent number: 9327021
    Abstract: The present invention provides compositions comprising a Chlamydial major outer membrane protein (referenced herein as “MOMP”), from at least one Chlamydial serovar and an adjuvant, characterized in that the adjuvant comprises the product E6020 having CAS Number 287180-63-6. The composition may further comprise at least one carrier system (e.g., emulsion, mineral particle). The MOMP protein may be derived from any species of Chlamydia (e.g., C. trachomatis, C. pneumoniae, C. psittaci, or C. trachomatis MoPn). In preferred embodiments, the composition comprises one or more major outer membrane proteins each derived from different serovars of C. trachomatis. The invention also provides methods of inducing an immune response to a Chlamydia species (e.g., C. trachomatis) in a subject, by administering to the subject a composition of the invention.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: May 3, 2016
    Assignees: Sanofi Pasteur Limited, Sanofi Pasteur S.A.
    Inventors: Scott Gallichan, Ausra Mancevski, Nathalie Reveneau, Jin Su, Francois Dalencon, Jean Haensler
  • Patent number: 9028839
    Abstract: The invention relates to a vaccine composition comprising: a) inactivated whole virus, and b) a stabilizing excipient which comprises: i. a buffer solution, ii. a mixture of essential and nonessential amino acids, iii. a disaccharide, iv. a polyol, v. a chelating agent, vi. urea or a urea derivative, and vii. a nonionic surfactant.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: May 12, 2015
    Assignee: Sanofi Pasteur S.A.
    Inventors: Alain Francon, Michel Chevalier, Nadege Moreno, Eric Calvosa, Sandrine Cigarini, Virginie Fabre
  • Patent number: 8703095
    Abstract: The invention relates to an oil-in-water adjuvant emulsion which comprises at least: squalene, an aqueous solvent, a polyoxyethylene alkyl ether nonionic surfactant, a hydrophobic nonionic surfactant, which emulsion is thermoreversible, and wherein 90% of the population by volume of the oil drops has a size less than 200 nm. The invention also relates to a process for preparing an immunogenic composition according to which at least one vaccine antigen is mixed with an oil-in-water emulsion, wherein the oil-in-water emulsion is obtained by means of a temperature-variation phase-inversion process.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: April 22, 2014
    Assignee: Sanofi Pasteur S.A.
    Inventors: Marie-Francoise Klucker, Francois Dalencon, Patricia Probeck-Quellec
  • Publication number: 20130344109
    Abstract: The present invention provides compositions comprising a Chlamydial major outer membrane protein (referenced herein as “MOMP”), from at least one Chlamydial serovar and an adjuvant, characterized in that the adjuvant comprises the product E6020 having CAS Number 287180-63-6. The composition may further comprise at least one carrier system (e.g., emulsion, mineral particle). The MOMP protein may be derived from any species of Chlamydia (e.g., C. trachomatis, C. pneumoniae, C. psittaci, or C. trachomatis MoPn). In preferred embodiments, the composition comprises one or more major outer membrane proteins each derived from different serovars of C. trachomatis. The invention also provides methods of inducing an immune response to a Chlamydia species (e.g., C. trachomatis) in a subject, by administering to the subject a composition of the invention.
    Type: Application
    Filed: November 15, 2011
    Publication date: December 26, 2013
    Applicants: SANOFI PASTEUR, S.A., SANOFI PASTEUR LIMITED
    Inventors: Scott Gallichan, Ausra Mancevski, Nathalie Reveneau, Jin Su, Francois Dalencon, Jean Haensler
  • Patent number: 8551527
    Abstract: The present invention relates to a process for stabilizing an adjuvant containing vaccine composition, an adjuvanted vaccine composition in dry form and in particular a process for stabilizing an influenza vaccine composition, particularly an adjuvanted influenza vaccine composition in dry form.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: October 8, 2013
    Assignee: Sanofi Pasteur S.A.
    Inventors: Pierre Chouvenc, Alain Francon
  • Patent number: 8506971
    Abstract: The subject of the invention is a method for adjuvanting LPS of a Gram-negative bacterium, according to which LPS or LPS liposomes (LPS formulated in liposomes) is (are) mixed with the lipidated human-transferrin receptor subunit B (TbpB protein) of Neisseria meningitidis or a lipidated fragment thereof; or (ii) LPS and the lipidated TbpB of N. meningitidis or a lipidated fragment thereof are formulated together in liposomes; or (iii) LPS is conjugated with the lipidated TbpB of N. meningitidis or a lipidated fragment thereof; in order to obtain a preparation which does not contain OMVs and which is capable of inducing, after administration to a mammal, an anti-LPS immune response which is improved by comparison with the anti-LPS immune response observed after administration of the corresponding preparation in which the lipidated TbpB of N. meningitidis or a lipidated fragment thereof is omitted; as well as vaccine compositions thereof.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: August 13, 2013
    Assignee: Sanofi Pasteur S.A.
    Inventors: Jean Haensler, Bruno Guy
  • Patent number: 8420805
    Abstract: The present invention relates to a process for preparing a porphyrin of formula (I), optionally in the form of a salt with an alkali metal and/or in the form of a metal complex: in which: R and R? are as defined in claim 1, comprising: a step of condensation, in an acidic medium, between a dipyrromethane of formula (II): in which R?b is as defined above for (I), and a dipyrromethane of formula (III): in which R? is as defined in claim 1, and also the compounds of formula (III).
    Type: Grant
    Filed: August 25, 2011
    Date of Patent: April 16, 2013
    Assignee: Sanofi Pasteur S.A.
    Inventors: Pierre Martin, Markus Mueller, Dirk Spielvogel, Dietmar Flubacher, Andreas Boudier
  • Patent number: 8377682
    Abstract: The present invention relates to a system for the heterologous expression of a viral protein or a fragment thereof, said system comprising a) a ciliate host cell, b) at least one cDNA encoding for a viral protein, or a fragment thereof, and c) a promoter operably linked to said cDNA.
    Type: Grant
    Filed: June 16, 2010
    Date of Patent: February 19, 2013
    Assignee: Sanofi Pasteur S.A.
    Inventors: Marcus Hartmann, Christine Sachse, Jenny Apelt, Ulrike Bockau
  • Patent number: 8338137
    Abstract: The invention relates to the type 5 and type 8 capsular polysaccharides produced by overproducing S. aureus strains, and also to the immunogenic compositions and the vaccines comprising said capsular polysaccharides.
    Type: Grant
    Filed: March 19, 2007
    Date of Patent: December 25, 2012
    Assignee: Sanofi Pasteur S.A.
    Inventors: Bachra Rokbi, Claude Meric, Noelle Mistretta, Philippe Talaga, Olivier Adam
  • Patent number: 8029798
    Abstract: The invention concerns a pharmaceutical composition for treating or preventing a certain number of infections caused by pathogenic agents such as bacteria, comprising as immunogen, one or several polyosides derived from one or several pathogenic agents. The polyosides are in the form of conjugates, coupled with a carrier protein. The composition contains at least two types of conjugates, each being at least characterised by a different protein carrier.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: October 4, 2011
    Assignee: Sanofi Pasteur S.A.
    Inventor: Odile Leroy
  • Patent number: 8026358
    Abstract: The present invention relates to a process for preparing a porphyrin of formula (I), optionally in the form of a salt with an alkali metal and/or in the form of a metal complex: in which: R and R? are as defined in claim 1, comprising: a step of condensation, in an acidic medium, between a dipyrromethane of formula (II): in which R?b is as defined above for (I), and a dipyrromethane of formula (III): in which R? is as defined in claim 1, and also the compounds of formula (III).
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: September 27, 2011
    Assignee: Sanofi Pasteur S.A.
    Inventors: Pierre Martin, Markus Mueller, Dirk Spielvogel, Dietmar Flubacher, Andreas Boudier
  • Publication number: 20110212129
    Abstract: The invention relates to a method for producing flu virus according to which: a) immunizing a hen by administering a flu vaccine to the hen, b) triggering embryogenesis in one or more eggs of the immunized hen, c) infecting the one or more embryonated eggs by inoculating a flu virus into the allantoic cavity of the eggs, d) incubating the one or more infected embryonated eggs under temperature and humidity conditions that allow replication of the virus, and e) harvesting the allantoic fluid of the one or more incubated eggs containing the virus.
    Type: Application
    Filed: December 7, 2010
    Publication date: September 1, 2011
    Applicants: SANOFI PASTEUR S.A., MERIAL LIMITED
    Inventors: Catherine Gerdil, Catherine Moste, Isabelle Legastelois, Michel Marie Joseph Bublot, François-Xavier Le Gros
  • Publication number: 20110207173
    Abstract: The subject matter of the present invention is a novel vector and the use thereof for producing a heterologous protein or a gene of interest, that can be used, for example, in the context of an immunization or gene therapy programme and concerns in particular a self-replicating vector lacking an antibiotic-resistance gene, comprising a sequence encoding the ccdA protein functionally linked to a first promoter, the sequence of the Cer locus and a heterologous sequence, functionally linked to a second promoter.
    Type: Application
    Filed: July 9, 2009
    Publication date: August 25, 2011
    Applicant: SANOFI PASTEUR S.A.
    Inventors: Regis Sodoyer, Denis Speck, Isabelle Peubez, Nicolas Chaudet
  • Patent number: 7968102
    Abstract: The invention relates to Dengue chimeric viruses which are less prone to accumulate point mutations and genetic variations. In these Dengue chimeric viruses, the NS5 gene, which encodes polymerase, has been replaced by the corresponding NS5 sequence of a Yellow Fever virus.
    Type: Grant
    Filed: January 4, 2007
    Date of Patent: June 28, 2011
    Assignee: Sanofi Pasteur S.A.
    Inventor: Marie-Jose Quentin-Millet
  • Publication number: 20110117123
    Abstract: The invention concerns a pharmaceutical composition for treating or preventing a certain number of infections caused by pathogenic agents such as bacteria, comprising as immunogen, one or several polyosides derived from one or several pathogenic agents. The polyosides are in the form of conjugates, coupled with a carrier protein. The composition contains at least two types of conjugates, each being at least characterised by a different protein carrier.
    Type: Application
    Filed: November 22, 2010
    Publication date: May 19, 2011
    Applicant: SANOFI PASTEUR S.A.
    Inventor: Odile Leroy
  • Patent number: 7871807
    Abstract: The invention relates to a method for producing flu virus according to which: a) immunizing a hen by administering a flu vaccine to the hen, b) triggering embryogenesis in one or more eggs of the immunized hen, c) infecting the one or more embryonated eggs by inoculating a flu virus into the allantoic cavity of the eggs, d) incubating the one or more infected embryonated eggs under temperature and humidity conditions that allow replication of the virus, and e) harvesting the allantoic fluid of the one or more incubated eggs containing the virus.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: January 18, 2011
    Assignee: Sanofi Pasteur, S.A.
    Inventors: Catherine Gerdil, Catherine Moste, Isabelle Legastelois, Michel Joseph Marie Bublot, Francois-Xavier Le Gros
  • Patent number: 7863013
    Abstract: The present invention relates to a method for the production of an overproducing Staphylococcus aureus strain comprising: (a) culturing a Staphylococcus aureus strain on a culture medium M1, M2 or M3, (b) optionally, recovering the strains thus produced from the culture medium, and also to the use of said strains for the production of polysaccharides.
    Type: Grant
    Filed: April 21, 2006
    Date of Patent: January 4, 2011
    Assignee: Sanofi Pasteur S.A.
    Inventors: Bachra Rokbi, Céline Lafont
  • Patent number: 7862823
    Abstract: The invention concerns a pharmaceutical composition for treating or preventing a certain number of infections caused by pathogenic agents such as bacteria, comprising as immunogen, one or several polyosides derived from one or several pathogenic agents. The polyosides are in the form of conjugates, coupled with a carrier protein. The composition contains at least two types of conjugates, each being at least characterised by a different protein carrier.
    Type: Grant
    Filed: May 14, 1998
    Date of Patent: January 4, 2011
    Assignee: Sanofi Pasteur S.A.
    Inventor: Odile Leroy
  • Patent number: 6927235
    Abstract: The present invention relates to vaccine compositions comprising iron phosphate as adjuvant. This iron phosphate is in the form of particles, the size of which is between 0.01 ?m and 300 ?m; it can be obtained by mixing a solution of iron salt and of phosphate salt.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: August 9, 2005
    Assignee: Sanofi Pasteur S.A.
    Inventor: Elisabeth Sauzeat